Press release
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting taking place in Munich, Germany from September 1-3. KalVista is a Silver-level sponsor of the meeting. The presentations are:\n\n\n\nIn Their Own Words - Patient Descriptions of the Earliest Recognition of HAE Attack Onset: Michael E. Manning, Autumn F. Burnette, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Mar Guilarte, Anna Valerieva (presenter only). Results shared as a poster presentation and Q&A\n\n\n\n\nRecognizing the Importance of Early On-Demand Treatment in the HAE Attack Journey: Douglas H. Jones, Princess Ogbogu, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Markus Magerl (presenter). Results shared as a poster presentation and Q&A\n\n\n\nAll poster presentations will take place on Friday, September 1 starting at 7:15 p.m. CEST in the Foyer on the 1st floor of the Westin Grand Hotel.\n\n\nKalVista will also be launching a new patient-focused site called “Mind the HAE Attack” at HAEi EMEA on September 1. Mind the HAE Attack has been developed with the HAE community to address the psychological and physical burdens of HAE attacks, and to create tools that support treatment at the onset of an attack. You can find the site at MindtheHAEattack.com.\n\n\nAbout KalVista Pharmaceuticals, Inc.\n\n\nKalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved its enrollment target for the phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.\n\n\nFor more information about KalVista, please visit www.kalvista.com.\n\n\nFor more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.\n\n\nForward...